USA, New Haven 
Dr. Maryam B. Lustberg is an internationally recognized breast medical oncologist, clinical investigator, and leader in supportive cancer care. She serves as Chief of Breast Medical Oncology and Professor of Medicine at Yale School of Medicine, and Deputy Director of the Division of Breast Oncology at Yale Cancer Center. She will be inducted as a Fellow of the American Society of Clinical Oncology (FASCO) in 2025.
Her work spans breast cancer therapeutics, survivorship science, digital health innovation, and national clinical trial leadership.
Education
- BS, University of Maryland, College Park (1993–1998)
- MD, University of Maryland, Baltimore (1999–2003)
- MPH, The Ohio State University (2008–2010)
Postgraduate Training
- Research Assistant, National Cancer Institute (1998–1999)
- Internship, University of Maryland Medical System (2003–2004)
- Residency, University of Maryland Medical System (2004–2006)
- Internal Medicine Hospitalist, University of Maryland (2006–2007)
- Advanced Fellow, Hematology‑Oncology, The Ohio State University (2007–2009)
- Breast Medical Oncology Fellowship, The Ohio State University (2009–2010)
Academic Appointments
- Professor of Medicine, Yale University (2024–present)
- Associate Professor of Medicine, Yale University (2021–2024)
- Tenured Professor, The Ohio State University (2021)
- Associate Professor, OSU James Cancer Hospital & Solove Research Institute (2017–2021)
- Assistant Professor (Tenure Track), The Ohio State University (2010–2017)
Leadership Roles
- Chief of Breast Medical Oncology, Yale School of Medicine (2021–present)
- Deputy Director, Division of Breast Oncology, Yale Cancer Center (2022–present)
- Co‑Chair, Alliance Clinical Trials Symptom Intervention Committee (2021–present)
- Director, Breast Center at Smilow Cancer Hospital (2021–2022)
- Medical Director, Supportive Care, OSU Comprehensive Cancer Center (2019–2021)
- Medical Director, Survivorship, OSU Comprehensive Cancer Center (2015–2019)
- Director, Breast Cancer Survivorship, OSU (2012–2021)
Board Certification
- American Board of Internal Medicine (2006–2026)
- Medical Oncology (2010–2031)
Research & Clinical Focus
- Breast cancer therapeutics (early‑stage and metastatic)
- Chemotherapy‑induced peripheral neuropathy
- Cognitive and affective effects of cancer treatment
- Digital symptom monitoring and AI‑enabled communication
- Endocrine therapy adherence and toxicity
- Lifestyle and non‑pharmacologic survivorship interventions
- Cooperative group trials in symptom science and supportive care
Current Grants & Clinical Trials (Selected)
(All details taken directly from the CV)
National Cancer Institute / NIH
- DAANCE Trial – Dance‑based non‑pharmacologic intervention for chemotherapy effects
Role: MPI
Period: 2024–2025 - Decision Support Tool for Surgical Decision‑Making in Young Women with Breast Cancer
Role: Co‑Investigator
Period: 2022–2025
American Cancer Society
- Molecular Etiology of Aggressive Screening‑Detected Breast Cancers
Role: Co‑Investigator
Period: 2024–2027
American Institute for Cancer Research
- MIND Diet Intervention in TNBC Survivors
Role: Co‑Investigator
Period: 2024–2026
Breast Cancer Research Foundation
- Adherence and Toxicity to CDK4/6 Inhibitors
Role: Co‑Investigator
Period: 2024–2025
AstraZeneca
- ImPACCT Trial: Improving Participation in Clinical Cancer Trials
Role: Principal Investigator
Period: 2024–2026
Lilly USA
- AI Tool for Identifying High‑Risk Recurrence in HR+/HER2‑ EBC
Role: Co‑PI
Period: 2024–2025
TBCRC (Johns Hopkins University)
- TBCRC Infrastructure Task Order
Role: Site PI
Period: 2022–2025
Pending Grants (Selected)
Department of the Army
- ctDNA‑Guided Adjuvant Therapy with Elacestrant
Role: Co‑Investigator
Period: 2025–2029
National Institutes of Health
- Chat‑ACCESS: AI‑Enabled Symptom Communication
- DX1‑LRRC31 Fusion Therapy for TNBC Brain Metastases
- Nanoparticle‑Based Siglec‑10 Blockade Therapy for Breast Cancer
Ohio State University / NCI
- Assessing Scanxiety Among Cancer Survivors (SADS Scale)
Role: Co‑Investigator
Period: 2025–2027
Past Major Grants (Selected)
(NIH, NCI, foundations, industry)
- Prevention of Paclitaxel‑Induced Neuropathy (R01) – MPI
- Novel Interventions for Chemotherapy‑Induced Neuropathy (R21) – MPI
- Affective Consequences of Chemotherapy (R01) – Co‑Investigator
- Cardiolipin‑Targeted Interventions for Muscle Health (R21) – Co‑Investigator
- Cognitive Deficits from Chemotherapy and Dietary Modulation (R01) – MPI
- Cardiovascular Risks in Breast Cancer Survivors (R01) – Co‑Investigator
- Curcumin for AI‑Induced Arthropathy (Alliance) – Co‑PI
- Fractional CO₂ Laser Therapy for Gynecologic Cancer Survivors (Alliance) – PI
- Ketogenic Diet and Chemotherapy Response (Hecht Foundation) – Co‑Investigator
Honors & Awards (Selected)
National & International
- Castle Connolly Exceptional Women in Medicine (multiple years)
- Top 5 Women in Digital Oncology, Health Europa (2023)
- Forbes Physician Honor Roll (2017)
- ASCO Young Investigator Award (2010)
- AACR–Susan G. Komen Scholar‑in‑Training Award (2010)
Institutional
- Yale Cancer Center Mentor of the Year Award (2024)
- OSU Outstanding Research Fellow Award (2009)
- Multiple OSU awards for patient satisfaction, mentorship, and teaching
Professional Impact
Dr. Maryam Lustberg is recognized for advancing patient‑centered oncology through clinical trial leadership, survivorship innovation, and national cooperative group service. Her work has shaped modern approaches to toxicity mitigation, digital symptom reporting, and supportive care delivery in breast cancer.